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Cost effectiveness of heptavalent pneumococcal conjugate vaccine
in populations of high risk in Colombia
NELSON ALVIS GUZMÁN, PhD1, FERNANDO DE LA HOZ, MD2
SUMMARY
Objective: To estimate the economic impact of the introduction of heptavalent pneumococcal conjugate vaccine (PCV-
7) in high risk populations of Colombia.
Methods: A full economic evaluation was done regarding potential introduction of PCV-7. A cost-effectiveness study
from the perspective of the third payer was done using a Decision Model. The model considered two alternatives: with and
without vaccination. As measurement of results the avoided events were taken [cases, hospitalizations, deaths and Life-Years
Saved (LYS)]. In addition the net costs and the incremental cost-effectiveness ratio (ICER) were evaluated.
Results: In a cohort of 70 thousand children of under 2 years old in situation of high risk, can generate 532 deaths that
would produce a little more than 21 thousand Years of Life Lost (YLL) with costs between 7.7 and 13.3 million dollars. If
we vaccinate this same cohort the deaths can be reduced to 355, and the costs of burden of disease would be between 5.7 and
10 million dollars. It is estimated a reduction of 25% of the costs of burden of disease and of 33% of the deaths. In addition
the  ICER by YLS would be between 590 and 762 dollars.
Conclusion: The introduction of the Heptavalent Pneumococcal Conjugate Vaccine in populations of high risk is highly
cost effective in Colombia.
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Costo efectividad de la vacuna conjugada heptavalente de neumococo en poblaciones de alto riesgo en Colombia.
El caso de la vacunación en niños de bajo peso al nacer
RESUMEN
Objetivo: Evaluar económicamente la introducción de la vacuna heptavalente de neumococo en poblaciones de alto
riesgo en Colombia.
Métodos: Se realizó un análisis de costo-efectividad desde la perspectiva del tercer pagador utilizando un modelo de
decisiones que consideró dos alternativas: con y sin programa de vacunación. Como medida de resultados se tomaron los
eventos evitados [casos, hospitalizaciones, muertes y años de vida salvados (AVS)]. Además, se valoraron los costos netos
y la razón de costo-efectividad incremental (RCEI).
Resultados: En una cohorte de 70 mil niños menores de dos años en situación de alto riesgo (bajo peso al nacer), se puede
generar 532 muertes que producirían un poco más de 21 mil años de vida perdidos. Los costos de atención estarían entre 7,7
y 13,3 millones de dólares. Si vacunásemos esta misma cohorte con la vacuna conjugada heptavalente las muertes se
reducirían a 355 y los costos de la carga estarían entre 5,7 y 10 millones de dólares. Es decir, una reducción cerca de 25%
de los costos de la carga y 33% de las muertes. Además el RCEI por AVS estaría entre 590 y 762 dólares del año 2006.
Conclusiones: La introducción de la vacuna contra neumococo en poblaciones de alto riesgo (bajo peso al nacer) en
Colombia es altamente costo-efectiva.
Colomb Med. 2010; 41: 315-22
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The success of the PAI strategy to improve health has
lead to improve the development of new vaccines to battle
other health diseases, such as pneumonia, meningitis,
hepatitis A, varicella and rotavirus. These new vaccines
have shown to have high efficacy and safety, and promise
to reduce even more the burden of disease in human
populations. However, due to the high vaccine introduction
prices in the market, the more vulnerable population, the
poorest without health insurer, are those who benefit the
least with this technological advances.
It is estimated that around a million children less
than 5 years old die annually due to invasive infections
associated to Streptococcus pneumoniae, even when
there are two polysaccharides vaccines in children
under 2 years. One of the vaccines, the most extensively
assessed, has seven serotypes that cause more than 85%
of the disease in United Sates, but have a lower coverage
in Colombia1. The serotypes in this vaccine are 4, 23F,
6B, 19F, 18C, 14 and 9V, which have an average
coverage of 62% for pneumococcal invasive disease in
Colombia. This is due to the lack of coverage of sero-
types 1 and 5 that frequently cause invasive disease in
our country and Latin America2. This event, tied to the
high cost of the vaccine, should encourage carefulness
in the analysis of the burden of disease of the possible
introduction of the vaccine and the balance of the
possible benefits of its introduction versus the cost.
One of the possible ways of action is to introduce the
vaccine in high risk populations, low birth weight, that
have a much higher incidence of pneumococcal disease
compared with normal weight children3-5. The present
study makes a cost-effectiveness analysis of the
heptavalent vaccine against pneumococco in high risk
populations of Colombia.
METHODS
To estimate the burden of disease of pneumococco
in high risk populations a model with the low birth
weight population under two years was done. It is
estimated that approximately 8-10% of Colombian
children born with less than 2,500 g, which represents
an annual cohort of 70,000 children. For the present
study it was assumed that children of two cohorts of live
births were followed from birth until two years of age.
One of the cohorts simulated a population without
vaccination, and the other assumed 90% of the children
received 3 doses of PCV-7. To estimate epidemiologic
parameters of frequency of disease and cost, information
about occurrence of invasive disease and pneumonia
due to pneumococcal disease in Latin America, from a
review realized by Savin Vaccine Institute in 20066. It
was assumed that risk of disease for each pneumococcal-
related syndrome was twice for children with low birth
weight, compared with normal birth weight5. The
estimations from the Sabin study are in Table 1.
The vaccine used in this analysis is a conjugated
vaccine of seven serotypes, produced by Wyeth®. Effi-
cacy and effectiveness of the heptavalent vaccine have
been extensively assessed in United States, but there are
still few studies of its effectiveness in other countries,
especially in developing countries. The effectiveness of
the vaccine for this study was estimated from the studies
of Black et al17,18. About the serotypes of the vaccine, the
adjustment because of the serotype distribution in
Colombia was not considered. A mean cost of the
vaccination was considered to be US$35 per dose, which
it is the price offered by Fondo Rotatorio de Vacunas of
Pan-American Health Organization (PAHO). For the
sensitivity analysis the price varied US$5.
To perform the cost-effectiveness analysis a decision
tree model was design (Figure 1), with two branches
that considered two alternatives (vaccination and not
vaccination). To model the decision tree the parameters
in Table 2 were used. Data was incorporated and
processed in a Microsoft Excel® 2007 spreadsheet.
Temporal horizon and perspective. For the analysis
cost and health outcomes of a cohort of children less
than two years old were assessed, for a year (after
vaccination), from the third payer perspective. For
international comparability, costs were expressed in
American dollars of 2006.
Outcome measures. As model outcome measures
avoided events were taken (cases, hospitalizations,
deaths, and life-years saved). Also, regarding the costs,
net costs and incremental cost-effectiveness (ICER)
were assessed. For the present study, ICER is the
difference between vaccination costs minus avoided
treatment cost, divided by life-years saved (LYS), as
shown in the following formula:
ICER =
Vaccination-related cost – Avoided treatment costs
Life-Years Saved
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Table 1
Incidence of pneumococco related disease
  Age group                                     Median of incidence per 105 (Q1-Q3)   Number of studies (References)
Invasive pneumococcal disease
  < 1 yr old 61 (58-63) 2 (7,8)
  < 2 yrs old 61 (52-71) 2 (7,8)
  < 5 yrs old 32 (32-33) 1 (8)
Pneumococcal meningitis
  < 1 yr old 19 1 (9)
  < 2 yrs old 12 1 (9)
  < 5 yrs old 12 4 (8,10-12)
All-cause pneumonia
  < 2 yrs old 4363 1 (13)
  < 5 yrs old 3059 (2957-3142) 2 (13,14)
All-cause radiological
confirmed pneumonia
  < 2 yrs old 2100 (1723-2375) 4 (7,13,15,16)
  < 5 yrs old 1174 (980-1613) 3 (13,15,16)
Pneumococcal pneumonia
  < 2 yrs old 51 (417-55) 2 (7,9)
  < 5 yrs old 34 1 (8)
Pneumococcal sepsis
  < 3 yrs old 2 1(8)
Figure 1. Decision tree to assess the cost-effectiveness of the introduction of the heptavalent vaccine in
population under 2 years old with high epidemiological risk in Colombia.
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Table 2
Parameters for the economic assessment of PCV-7 in high risk populations
  Model parameters Base Plausible range References
Inferior limit   Superior limit
Demographic   
  Population <2 yrs old at risk 70 mill — — Actual analysis
  Life expectancy < 2 yrs old 72,0 — —
  Discount rate 3%   
Disease incidence Table 1
Attention cost (U$ 2006)   
  Invasive pneumococcal disease 1300,5 1132,38 1543,26 (6)
   Meningitis 1303,7 1059,24 2761,42
  Clinically-diagnosed pneumonia 92,5 77,82 220,59
  Radiological-diagnosed pneumonia 885,9 866,93 1325,29
   Pneumococcal pneumonia 885,9 866,93 1325,3
   Otitis media 93,9 90,7 170,05
Efficacy of pneumococcal vaccination   
  Invasive pneumococcal disease 0,65 0,60 0,75 (17,18)
   Meningitis 0,65 0,60 0,75
  Clinically-diagnosed pneumonia 0,12 0,70 0,15
  Radiological-diagnosed pneumonia 0,20 0,15 0,25
   Pneumococcal pneumonia 0,65 0,60 0,75
   Otitis media 0,07 0,04 0,10
Number of vaccine doses 3 Ministerio de la
Protección Social
Cost for each vaccine dose U$35 U$5 U$35
Addministrative cost for each vaccine dose U$1.0 U$0.5 U$1.50
As the recommended by WHO’s Commission on
Macroeconomics and Health19 a strategy was considered
very cost-effective if the cost for avoided DALY is less
than the gross domestic product (GDP) per capita; if
that cost was below three times the GPD per capita, the
strategy was considered cost-effective; finally, if it is
above three times the GDP per capita, the strategy is not
cost-effective. For Colombia, according to Banco de la
República, in 2006 the GDP per capita was US$3,745.
Sensitivity analysis. To evaluate the robustness of
the results, a deterministic univariate sensitivity analysis
was performed, using inferior and superior epide-
miologic and cost parameters, as shown in Table 2.
Also, a scenario analysis was performed simulating the
best and worst epidemiologic scenario with base on the
disease incidence.
RESULTS
In a cohort of 70 thousands children under two years
of age with low birth weight (<2,500 g), there are 532
generated deaths as a product of the events related in
Table 3. These deaths would produce 21 thousand years
of life lost, with cost between 7.7 and 13.3 million
dollars. If we vaccinate that same cohort, deaths could
be reduce to 355, and burden cost would be between 5.7
and 10 million dollars. That means a reduction of nearly
25% of the burden costs and 33% of deaths.
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Table 3
Cost of pneumococcal burden of disease in children less than 2 years old with high
epidemiological risk Colombia 2007 (2006 US$)
Events and cost with                        Expected           Years of                            Total cost
       vaccination                                 cases     deaths       life lost       Total             Inf lim             Sup lim
Invasive pneumococcal disease 35 14 560 46.620,0 39.633,3 54.014,1
Meningitis 35 14 560 46.830,0 37.073,4 96.649,7
Clinically-diagnosed pneumonia 11.200 224 8.960 1.030.400,0 871.584,0 2.470.608,0
Radiological-diagnosed pneumonia 5.600 112 4.480 4.961.600,0 4.854.808,0 7.421.624,0
Pneumococcal pneumonia 1.400 168 6.720 1.240.400,0 1.213.702,0 1.855.420,0
Otitis media 7.875 - - 732.375,0 714.262,5 1.339.143,8
Total 532 21.280 8.058.225 7.731.063 13.237.460
Events and costs with vaccination
Invasive pneumococcal disease 12 5 196 16.317,0 13.871,7 18.904,9
Meningitis 12 5 196 16.390,5 12.975,7 33.827,4
Clinically-diagnosed pneumonia 9.856 197 7.885 906.752,0 766.993,9 2.174.135,0
Radiological-diagnosed pneumonia 4.480 90 3.584 3.969.280,0 3.883.846,4 5.937.299,2
Pneumococcal pneumonia 490 59 2.352 434.140,0 424.795,7 649.397,0
Otitis media 7.324 - - 681.108,8 664.264,1 1.245.403,7
Total 355 14.213 6.023.988 5.766.747 10.058.967
Avoided events and cost              Expected           Years of                           Total cost
    with  vaccination                        cases     deaths     life lost          Total             Inf lim             Sup lim
Invasive pneumococcal disease 23 9 364 30.303,0 25.761,6 35.109,2
Meningitis 23 9 364 30.439,5 24.097,7 62.822,3
Clinically-diagnosed pneumonia 1.344 27 1.075 123.648,0 104.590,1 296.473,0
Radiological-diagnosed pneumonia 1.120 22 896 992.320,0 970.961,6 1.484.324,8
Pneumococcal pneumonia 910 109 4.368 806.260,0 788.906,3 1.206.023,0
Otitis media 551 - - 51.266,3 49.998,4 93.740,1
Total 177 7.067 2.034.236,8 1.964.315,7 3.178.492,3
To vaccinate 70 thousands children with the three
doses of the PCV-7 cost 7.3 million dollars, which
would avoid treatment cost between 2 and 3.2 million
dollars. This will generate net cost between 4.1 and 5.3
million dollars. With these costs, ICER of life-years-
saved would be between 590 and 762 dollars, and ICER
of avoided death would be between 23,611 and 30,483
dollars (Table 4).
For the sensitivity analysis an on-way analysis was
done with all variables that entered in the model, which
established which variables influenced the model the
most. These variables, for the present model, were
cumulative incidences of pneumococcal invasive disease
and pneumonias. With these results, different
epidemiologic scenes (best and worst) were defined.
ICER results of life-years saved between 845 and 1026
US$/LYS (best scene), and 422 and 489 US$/LYS
(worst scene) (Table 4).
DISCUSSION
The results of the present study suggest that
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Table 4
Net costs and ICER of the Colombian vaccination program in chldren less than 2 years old with
high epidemiological risk Colombia 2007 (2006 US$)
Base epidemiological scene   Base case  Inf lim Sup lim
Direct costs of attention  8.058.225  7.731.063  13.237.460
Vaccination costs  7.350.000  7.350.000  7.350.000
Avoided cost of after vaccination  2.034.237  1.964.316  3.178.492
Net costs 5.315.763 5.385.684 4.171.508
ICER U$/LYG  752  762  590
ICER U$/avoided death  30.087  30.483  23.611
    Worst epidemiological scene Caso base  Lim inf Lim sup
Direct costs of attention  9.281.839  8.907.847  15.234.615
Vaccination costs  7.350.000  7.350.000  7.350.000
Avoided cost of after vaccination  2.397.654  2.315.913  3.740.849
Net costs  4.952.346  5.034.087  3.609.151
ICER U$/LYG  579  589  422
ICER U$/avoided death  23.166  23.548  16.883
Best epidemiological scene Caso Base  Lim Inf Lim Sup
Direct costs of attention  6.980.435  6.696.497  11.506.943
Vaccination costs  7.350.000  7.350.000  7.350.000
Avoided cost of after vaccination  1.681.027  1.622.673  2.634.801
Net costs  5.668.973  5.727.327  4.715.199
ICER U$/LYG  1.015  1.026  845
ICER U$/avoided death  40.615  41.033  33.781
Table 5
Cost-effectiveness of the interventions for the treatment of acute respiratory disease
due to pneumonia (2001 Dollars/DALY)
  Region                                                           Non severe (level)                         Severe        All the interventions
                                                               community    institutional    hospital       hospital level
Low and middle income-countries 208 50 2.916 6.144 398
East-Asia and Pacific 439 91 6.511 13.945 900
Latin America and the Caribbean 547 424 14.719 28.106 1.941
Middle-east and north Africa 733 180 6.810 13.438 1.060
South Asia 140 28 1.931 4.318 264
Sub-Saharan Africa 139 24 1.486 3.376 218
Source: Reference 24
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vaccination against pneumococco in children of low
birth weight is very cost-effective. There is a high
possibility that the results are conservative, because we
assumed the risk of acquiring pneumococcal disease in
children with low birth weight to be twice compared
with the children with normal birth weight. It is possible
that this risk is really higher, as some studies in Colom-
bia have shown20.
The economic evaluation of the incorporation of the
PCV-7  in national programs of vaccination has been
studied in developed countries, showing ICER is highly
sensitive to vaccine prices and the incorporation of
vaccination herd immunity. In Norway, for example,
for a •$54 vaccine dose, the vaccination is not cost-
effective at a threshold of 54 thousands Euros for
LYG21. Similar results are present in Canada, when it is
concluded that only with a vaccine below 30 dollars per
dose, costs from the societal perspective would be
save22.
On the other hand, Beutels et al.23, in a review of 15
studies of the vaccine economic evaluation, establish
that Finland, Australia, England, Netherlands, and
Canada, the pneumococcal vaccination against pneumo-
cocco (PCV7) was reported less cost-effective than
dialysis and screening for breast cancer (Finland);
screening of cervical or breast cancer (Australia),
vaccination against meningococcus C or influenza
(Netherlands), vaccination against pneumococco in
adults (with pneumococcal polysaccharide vaccine) or
varicella (Canada). Nevertheless, universal vaccination
with PCV7 was cost-effective in Spain, Canada and
Germany (from the societal perspective).
Table 5 shows the cost-effectiveness of assisting
pneumonia cases in Latin America and the Caribbean24
and see that avoid a disability-adjusted life year (DALY)
is worth 1941 dollars, while with vaccination, this
study shows that with vaccination to avoid the same
year of life cost around 579 dollars in the most favora-
ble scene of vaccination and 1015 in the most
unfavorable. Even in the worst scene of vaccination in
our country, the cost-effectiveness results in high risk
populations are much more important than developed
countries3,4.
In the present study a cost of 35 dollars per vaccine
is assumed (which it is an extremely high cost for a
developed country), but the epidemiological situation
is different (population at risk), for which the cost-
effectiveness has an acceptable margin, according to
WHO parameters19. For this high risk population, a
three dose vaccine with the proposed prices, the
intervention with the heptavalent is in the same range of
the 80% of the interventions that the country has for
prevention and control (less than 1000 dollars per
disability-adjusted life year). The sensitivity analysis
of the scenes shows how the results are robust given the
variation of epidemiological parameters.
It is important to make clear that the cost-
effectiveness analysis only is not the most important
fundament for decision analysis. This should be
accompanied with the evaluation of the budget impact
on the health system that the incorporation of the new
technology represents, with prices that could not be
financially sustainable if the intervention were cost-
effective, as it happens currently with some vaccines.
The limitations the present study include the fact
that cost parameters are from literature review and not
from studies of disease costs for specific populations,
as assumed. Besides, our model does not consider the
herd immunity effect of vaccination, which could
underestimate the true results of the model. However,
the sensitivity analysis of minimum and maximum
scenes that was made could in part correct this limitation.
Conflict of interest. None of the authors has conflicts
of interest related to this study.
ACKNOWLEDGEMENTS
The authors would like to thank the Ministerio de
Protección Social (Ministry of Social Protection), Pro-
grama Ampliado de Inmunizaciones, for the help in the
realization of the present research.
REFERENCES
1. Agudelo CI, Moreno J, Sanabria OM, Ovalle MV, Di Fabio
JL, Castañeda E. Streptococcus pneumoniae: serotype
evolution and patterns of antimicrobial susceptibility in invasive
isolates from 11 years surveillance (1994-2004) in Colombia.
Biomedica. 2006; 26: 234-49.
2. Di Fabio JL, Castaneda E, Agudelo CI, De La HF, Hortal M,
Camou T, et al. Evolution of Streptococcus pneumoniae
serotypes and penicillin susceptibility in Latin America, Sireva-
Vigia Group, 1993 to 1999. PAHO Sireva-Vigia Study Group.
Pan American Health Organization. Pediatr Infect Dis J.
2001; 20: 959-67.
3. Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Cost-
effectiveness of heptavalent conjugate pneumococcal vaccine
322
Colombia Médica                  Vol. 41 Nº 4, 2010 (Octubre-Diciembre)
(Prevenar) in Germany: considering a high-risk population
and herd immunity effects. Eur J Health Econ. 2008; 9: 7-15.
4. Finn A, Booy R, Moxon R, Sharland M, Heath P. Should the
new pneumococcal vaccine be used in high-risk children?
Arch Dis Child. 2002; 87: 18-21.
5. Mahon BE, Ehrenstein V, Norgaard M, Pedersen L, Rothman
KJ, Sorensen HT. Perinatal risk factors for hospitalization for
pneumococcal disease in childhood: a population-based cohort
study. Pediatrics. 2007; 119: e804-12.
6. Constenla D, Gómez E, De la Hoz F, O’Loughlin R, Sinha A,
Valencia J, et al. The burden of pneumococcal disease and the
cost effectiveness of a pneumococcal vaccine in Latin America
and the Caribbean: A review of the evidence and a preliminary
economic analysis. Washington, DC: The Albert B. Sabin
Vaccine Institute (SVI); 2007. [fecha de acceso en noviembre
de 2007]. URL disponible en: http://www.sabin.org/files/
attachment sabinreportfinal2.pdf
7. Tregnaghi M, Ceballos A, Ruttimann R, Ussher J, Tregnaghi
P, Peeters P, et al. Active epidemiologic surveillance of
pneumonia and invasive pneumococcal disease in ambulatory
and hospitalized infants in Cordoba, Argentina. Pediatr Infect
Dis J. 2006; 25: 370-2.
8. Lagos R, Muñoz A, Valenzuela MT, Heitmann I, Levine MM.
Population-based surveillance for hospitalized and ambulatory
pediatric invasive pneumococcal disease in Santiago, Chile.
Pediatr Infect Dis J. 2002; 21: 1115-23.
9. Lagos Zuccone R, San Martín B O, Erazo L A, Avendaño-
Bertoló A, Levine M. Epidemiología de las enfermedades
invasoras causadas por Streptococcus pneumoniae en niños
chilenos: proyecciones clínicas y de salud pública. Rev Chil
Infectol. 2001; 18: 15-21.
10. Dickinson FO, Pérez AE. Bacterial meningitis in children and
adolescents: an observational study based on the national
surveillance system. BMC Infect Dis. 2005; 5: 103.
11. Reis JN, Cordeiro SM, Coppola SJ, Salgado K, Carvalho MG,
Teixeira LM, et al. Population-based survey of antimicrobial
susceptibility and serotype distribution of Streptococcus
pneumoniae from meningitis patients in Salvador, Brazil. J
Clin Microbiol. 2002; 40: 275-7.
12. Asturias EJ, Soto M, Menéndez R, Ramírez PL, Recinos F,
Gordillo R, et al. Meningitis and pneumonia in Guatemalan
children: the importance of Haemophilus influenzae type b
and Streptococcus pneumoniae. Rev Panam Salud Publica.
2003; 14: 377-84.
13. Hortal M EM, Iraola I, De Mucio B. A population-based
assessment of the disease burden of consolidated pneumonia
in hospitalized children under five years of age. Int J Infect
Dis. 2007; 11: 273-7.
14. Barreto ML SL, Assis AM, Araujo MP, Farenzena GG, Santos
PA, et al. Effect of vitamin A supplementation on diarrhoea
and acute lower-respiratory-tract infections in young children
in Brazil. Lancet. 1994; 344: 228-31.
15. Gentile A, Ruvinsky R, Bakir J, Gentile F, Kupervaser M,
Quiriconi M, et al. Surveillance of probably bacterial
pneumonia (PBP) in children less than 5 years old in two
geographical areas in Argentina. 45th Interscience Conference
on Antimicrobial Agents and Chemotherapy. Washington,
DC: American Microbiology Society; 2005.
16. Lagos RMA, Espinoza A, Moene K, Hausdorff W, Ruttimann
R, et al. Population-based surveillance for suspected (S) and
radiologically-confirmed (RxC) community acquired
pneumonia (CAP) in children 1-35 months of age (MoA), in 6
municipalities (Mn) of the metropolitan region (MR), Chile.
5th International Symposium on Pneumococci and
Pneumococcal Diseases 2006. Alice Springs, Elsevier.
17. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR,
et al. Efficacy, safety and immunogenicity of heptavalent
pneumococcal conjugate vaccine in children. Northern
California Kaiser Permanente Vaccine Study Center Group.
Pediatr Infect Dis J. 2000; 19: 187-95.
18. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B,
Spring D, et al. Effectiveness of heptavalent pneumococcal
conjugate vaccine in children younger than five years of age
for prevention of pneumonia. Pediatr Infect Dis J. 2002; 21:
810-5.
19. WHO. Macroeconomics and health: investing in health for
economic development. Report of the Commission on
Macroeconomics and Health. Geneva: World Health
Organization; 2001.
20. De la Hoz F, Higuera AB, Di Fabio JL, Luna M, Naranjo AG,
de la Luz Valencia M, et al. Effectiveness of Haemophilus
influenzae type b vaccination against bacterial pneumonia in
Colombia. Vaccine. 2004; 23: 36-42.
21. Wisloff T, Abrahamsen TG, Bergsaker MA, Lovoll O, Moller
P, Pedersen MK, et al. Cost effectiveness of adding 7-valent
pneumococcal conjugate (PCV-7) vaccine to the Norwegian
childhood vaccination program. Vaccine. 2006; 24: 5690-9.
22. De Wals P, Petit G, Erickson LJ, Guay M, Tam T, Law B, et
al. Benefits and costs of immunization of children with
pneumococcal conjugate vaccine in Canada. Vaccine. 2003;
21: 3757-64.
23. Beutels P, Thiry N, Van Damme P. Convincing or confusing?
Economic evaluations of childhood pneumococcal conjugate
vaccination: a review (2002-2006). Vaccine. 2007; 25: 1355-
67.
24. Simoes E, Cherian T, Chow J, Shahid-Salles S, Laxminarayan
R, T. J. Acute respiratory infections in children. In: Jamison
D, Breman J, Measham A, Alleyne G, Claeson M, Evans D, et
al. (eds). Disease control priorities in developing countries.
2nd ed. New York: The World Bank; 2006. p. 483-97.
